Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 8,376 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Terminated Phase 1Phase 2 Interventional Results available

Effects of Pioglitazone on Stress Reactivity and Alcohol Craving (Pilot)

NCT03860753
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Pioglitazone, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
21 Years to 40 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 1 Interventional

Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder

NCT00829881
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Betahistine Hydrochloride, Placebo Capsule
Drug
Lead sponsor
P2D, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 23, 2026, 1:54 PM EDT
Not yet recruiting Phase 2 Interventional

Pregnenolone Treatment for Alcohol Use Disorder and Major Depressive Disorder

NCT07734701
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
Sherwood Brown, MD, PhD
Other
Eligibility
21 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Dallas, Texas • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate GBT021601 in Single and Multiple Doses in Healthy Participants

NCT05036512
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
GBT021601
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 23, 2026, 1:54 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers Results available

The Efficacy of Probiotics to Reduce Antepartum Group B Streptococcus Colonization.

NCT03696953
View directory record Official record
Conditions
Group B Streptococcus Carrier in Childbirth, Gastrointestinal Symptoms
Interventions
Florajen3
Biological
Lead sponsor
Marquette University
Other
Eligibility
18 Years and older · Female only
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 23, 2026, 1:54 PM EDT
Recruiting Phase 2 Interventional

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, Elacestrant, Z-endoxifen
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
29
States / cities
Berkeley, California • Duarte, California • Irvine, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 2 Interventional

Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects

NCT04251182
View directory record Official record
Conditions
Alzheimer Disease
Interventions
15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 23, 2026, 1:54 PM EDT
Recruiting Phase 2 Interventional

A Study Utilizing Escitalopram in Glioma Patients

NCT03728673
View directory record Official record
Conditions
Glioma of Brain, Glioma
Interventions
Escitalopram Oral Capsules
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 1:54 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders

NCT04725383
View directory record Official record
Conditions
Autism Spectrum Disorder, Repetitive Compulsive Behavior
Interventions
amitriptyline
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison of Various Combinations of BiDil Capsules and BiDil Tablets in Healthy Human Volunteers

NCT01587313
View directory record Official record
Conditions
Healthy
Interventions
Isosorbide dinitrate / hydralazine capsules
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients

NCT00765661
View directory record Official record
Conditions
Kidney Failure, Renal Failure
Interventions
Tacrolimus (Tacro™), Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

NCT03308942
View directory record Official record
Conditions
Neoplasms
Interventions
Niraparib, Pembrolizumab, TSR-042 (Dostarlimab)
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

NCT04375397
View directory record Official record
Conditions
CoronaVirus Induced Disease-2019 (COVID-19)
Interventions
Ibrutinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Chronic Dietary Grape Seed Extract Supplementation on Aortic Stiffness and Hemodynamic Responses to Exercise in Obese Males

NCT04465110
View directory record Official record
Conditions
Obesity Adult Onset
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 3 Interventional Results available

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Gilbert, Arizona • Clovis, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions

NCT01581879
View directory record Official record
Conditions
Healthy
Interventions
Ziprasidone Hydrochloride
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 2 Interventional Results available

Cefixime for Alternative Syphilis Treatment

NCT03660488
View directory record Official record
Conditions
Syphilis, Early Syphilis
Interventions
Cefixime 400 milligram Oral Capsule [Suprax], Benzathine Penicillin G
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Beverly Hills, California • Los Angeles, California • Oakland, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

NCT00928083
View directory record Official record
Conditions
Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions
OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion
Drug
Lead sponsor
Medicines for Malaria Venture
Other
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Not applicable Interventional Results available

A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia

NCT01232790
View directory record Official record
Conditions
Schizophrenia
Interventions
N-Acetylcysteine, Placebo
Dietary Supplement · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

L-Citrulline and Endothelial Function

NCT05722860
View directory record Official record
Conditions
Aging
Interventions
L-Citrulline, capsule
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 23, 2026, 1:54 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

NCT05169060
View directory record Official record
Conditions
Diabetic Neuropathies
Interventions
Fish Oil Concentrate, 1000 Mg Oral Capsule, Salsalate Oral Tablet
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 23, 2026, 1:54 PM EDT
Terminated Phase 1 Interventional Results available

Phase 1 Trial of Oral Ixabepilone

NCT00632424
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Ixabepilone (oral formulation)
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Stanford, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Oct 23, 2026, 1:54 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

NCT05667662
View directory record Official record
Conditions
ABPA
Interventions
Itraconazole Powder, Placebo
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 23, 2026, 1:54 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596
View directory record Official record
Conditions
Epilepsy, Partial Seizures
Interventions
Pregabalin add-on therapy
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
4 Years to 16 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 23, 2026, 1:54 PM EDT